Specific situations warranting medical discussion include: Sudden or marked decrease in sexual desire that affects quality of life or relationships New onset of erectile dysfunction or difficulty achieving or maintaining arousal Changes in menstrual patterns, particularly irregular periods or amenorrhea Symptoms suggesting hormonal imbalance, such as fatigue, mood changes, or hot flashes Sexual dysfunction accompanied by other concerning symptoms like depression, severe fatigue, or relationship distress Any sexual health changes that cause significant personal concern, regardless of severity Seek immediate medical attention for these urgent symptoms: Severe, persistent abdominal pain (possible pancreatitis) Right upper quadrant pain with fever or yellowing of skin/eyes (possible gallbladder disease) Sudden vision changes (possible retinopathy complications) Signs of dehydration or decreased urination (possible acute kidney injury) New or worsening depression or suicidal thoughts (particularly with Wegovy) Your healthcare provider can conduct a thorough assessment to identify potential contributing factors
Growth hormone-releasing hormone effects on brain gamma-aminobutyric acid levels in mild cognitive impairment and healthy aging
In October 2024, tirzepatide was removed from the FDA drug shortage list, improving availability for patients
The proposed rules call for stability studies that far exceed FDA and USP standards, and which will cost compounding pharmacies $10,000 to $30,000 per formulation, according to Scott Brunner, CEO of the trade group Alliance for Pharmacy Compounding
Decision 03 Serum architecture Sealed-vial-to-head connection
